HK1092141A1 - Matrix metalloproteinase inhibitors - Google Patents

Matrix metalloproteinase inhibitors

Info

Publication number
HK1092141A1
HK1092141A1 HK06112572.5A HK06112572A HK1092141A1 HK 1092141 A1 HK1092141 A1 HK 1092141A1 HK 06112572 A HK06112572 A HK 06112572A HK 1092141 A1 HK1092141 A1 HK 1092141A1
Authority
HK
Hong Kong
Prior art keywords
alkyl
alkylaryl
cor
optionally substituted
bond
Prior art date
Application number
HK06112572.5A
Other languages
English (en)
Inventor
Simon Gaines
Ian Peter Holmes
Stephen Lewis Martin
Stephen Paul Watson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HK1092141A1 publication Critical patent/HK1092141A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
HK06112572.5A 2003-09-13 2006-11-15 Matrix metalloproteinase inhibitors HK1092141A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0321538.1A GB0321538D0 (en) 2003-09-13 2003-09-13 Therapeutically useful compounds
PCT/EP2004/010319 WO2005026120A1 (en) 2003-09-13 2004-09-10 Matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
HK1092141A1 true HK1092141A1 (en) 2007-02-02

Family

ID=29227079

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06112572.5A HK1092141A1 (en) 2003-09-13 2006-11-15 Matrix metalloproteinase inhibitors

Country Status (29)

Country Link
US (3) US7601729B2 (ko)
EP (3) EP2295408A1 (ko)
JP (3) JP2007505081A (ko)
KR (3) KR20060120648A (ko)
CN (1) CN1849306B (ko)
AT (2) ATE413384T1 (ko)
AU (1) AU2004272280C1 (ko)
BR (1) BRPI0413791A (ko)
CA (1) CA2538315C (ko)
CY (1) CY1109400T1 (ko)
DE (2) DE602004031991D1 (ko)
DK (1) DK1663970T3 (ko)
ES (2) ES2314436T3 (ko)
GB (1) GB0321538D0 (ko)
HK (1) HK1092141A1 (ko)
HR (1) HRP20080668T3 (ko)
IL (1) IL173305A (ko)
IS (2) IS2622B (ko)
MA (1) MA28039A1 (ko)
MX (1) MXPA06002458A (ko)
NO (1) NO20060540L (ko)
NZ (2) NZ573479A (ko)
PL (1) PL1663970T3 (ko)
PT (1) PT1663970E (ko)
RU (2) RU2370488C2 (ko)
SG (1) SG145685A1 (ko)
SI (1) SI1663970T1 (ko)
WO (1) WO2005026120A1 (ko)
ZA (1) ZA200602070B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321538D0 (en) * 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
ES2381681T3 (es) * 2005-02-22 2012-05-30 Ranbaxy Laboratories Limited Derivados de ácido 5-fenil-pentanoico como inhibidores de la metaloproteinasa matriz para el tratamiento del asma y otras enfermedades
AU2013200728B2 (en) * 2006-08-22 2014-12-18 Sun Pharmaceutical Industries Limited Matrix metalloproteinase inhibitors
CN101528691B (zh) * 2006-08-22 2014-11-26 兰贝克赛实验室有限公司 基质金属蛋白酶抑制剂
US7858666B2 (en) 2007-06-08 2010-12-28 Mannkind Corporation IRE-1α inhibitors
FR2949463B1 (fr) * 2009-08-26 2011-09-16 Commissariat Energie Atomique Inhibiteurs de mmp
AU2011284397A1 (en) 2010-07-30 2013-02-21 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
US20140148459A1 (en) 2010-09-24 2014-05-29 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
US20160045463A1 (en) 2012-11-28 2016-02-18 Universidad De Salamanca Use of metalloprotease inhibitors in the treatment of polycystic liver diseases
MD3413892T2 (ro) 2016-02-12 2022-06-30 Cytokinetics Inc Derivați de tetrahidroizochinolină
CN110769866B (zh) * 2017-06-13 2022-07-29 爱惜康有限责任公司 具有可控愈合的外科缝合器

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4102024A1 (de) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AU2199195A (en) * 1994-04-28 1995-11-29 Uniroyal Chemical Company, Inc. Fungicidal azole derivatives
TR199801000T2 (xx) * 1995-12-06 1998-08-21 Astra Pharmaceuticals Ltd. Bile�ikler
AU725847B2 (en) 1996-04-19 2000-10-19 Merck Sharp & Dohme B.V. Substituted benzylamines and their use for the treatment of depression
CO4990925A1 (es) * 1996-05-15 2000-12-26 Bayer Corp Acidos oxibutiricos sustituidos como inhibidores de la metaloproteasa de matriz
US5789605A (en) * 1996-12-03 1998-08-04 Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactones and mimics thereof
US6096904A (en) * 1996-12-03 2000-08-01 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US6870058B2 (en) * 1996-12-03 2005-03-22 The Trustees Of The University Of Pennsylvania Compounds which mimic the chemical and biological properties of discodermolide
US20050065353A1 (en) * 1996-12-03 2005-03-24 Smith Amos B. Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof
US6242616B1 (en) * 1996-12-03 2001-06-05 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US5804581A (en) * 1997-05-15 1998-09-08 Bayer Corporation Inhibition of matrix metalloproteases by substituted phenalkyl compounds
US6608052B2 (en) * 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
CA2490819A1 (en) * 2001-04-13 2002-10-24 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
WO2004012663A2 (en) 2002-08-01 2004-02-12 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
BR0314898A (pt) * 2002-11-19 2005-08-02 Galderma Res & Dev Compostos, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica
GB0312654D0 (en) * 2003-06-03 2003-07-09 Glaxo Group Ltd Therapeutically useful compounds
GB0314488D0 (en) 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
GB0319069D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
GB0321538D0 (en) * 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
ES2381681T3 (es) * 2005-02-22 2012-05-30 Ranbaxy Laboratories Limited Derivados de ácido 5-fenil-pentanoico como inhibidores de la metaloproteinasa matriz para el tratamiento del asma y otras enfermedades
CN101528691B (zh) * 2006-08-22 2014-11-26 兰贝克赛实验室有限公司 基质金属蛋白酶抑制剂

Also Published As

Publication number Publication date
JP2011231118A (ja) 2011-11-17
CA2538315A1 (en) 2005-03-24
KR20060120648A (ko) 2006-11-27
DE602004017622D1 (de) 2008-12-18
IL173305A (en) 2011-01-31
RU2006106850A (ru) 2007-10-20
CA2538315C (en) 2014-04-08
IS8268A (is) 2006-01-26
CN1849306A (zh) 2006-10-18
PL1663970T3 (pl) 2009-04-30
CN1849306B (zh) 2014-01-29
US8263602B2 (en) 2012-09-11
US7601729B2 (en) 2009-10-13
EP1663970A1 (en) 2006-06-07
ES2314436T3 (es) 2009-03-16
PT1663970E (pt) 2009-01-09
RU2370488C2 (ru) 2009-10-20
BRPI0413791A (pt) 2006-11-07
US20100029699A1 (en) 2010-02-04
IS8843A (is) 2009-08-19
AU2004272280C1 (en) 2011-10-27
DE602004031991D1 (de) 2011-05-05
ATE413384T1 (de) 2008-11-15
EP2042488B1 (en) 2011-03-23
US20090082377A1 (en) 2009-03-26
KR20120007566A (ko) 2012-01-20
NZ573479A (en) 2010-09-30
US20060293353A1 (en) 2006-12-28
SI1663970T1 (sl) 2009-04-30
NO20060540L (no) 2006-04-04
JP2012107031A (ja) 2012-06-07
SG145685A1 (en) 2008-09-29
AU2004272280A1 (en) 2005-03-24
HRP20080668T3 (en) 2009-02-28
US8343986B2 (en) 2013-01-01
MA28039A1 (fr) 2006-07-03
ES2362954T3 (es) 2011-07-15
ZA200602070B (en) 2007-05-30
IL173305A0 (en) 2006-06-11
KR20130079628A (ko) 2013-07-10
CY1109400T1 (el) 2014-07-02
GB0321538D0 (en) 2003-10-15
DK1663970T3 (da) 2009-01-12
MXPA06002458A (es) 2006-06-20
ATE502922T1 (de) 2011-04-15
IS2622B (is) 2010-05-15
EP2042488A1 (en) 2009-04-01
JP2007505081A (ja) 2007-03-08
RU2008146479A (ru) 2010-06-20
WO2005026120A1 (en) 2005-03-24
NZ545211A (en) 2009-01-31
AU2004272280B2 (en) 2011-04-21
EP1663970B1 (en) 2008-11-05
EP2295408A1 (en) 2011-03-16

Similar Documents

Publication Publication Date Title
HRP20080668T3 (en) Matrix metalloproteinase inhibitors
ATE362910T1 (de) Matrix metalloprotease inhibitoren
BR0201697A (pt) Compostos de alfa-aminoácid0, processo para a sua preparação e composições farmacêuticas contendo os mesmos
IL154893A0 (en) Aliphatic nitrogen-containing cyclic compounds, methods for the preparation thereof and pharmaceutical compositions containing the same
HUP0201475A2 (hu) Heteroarilamidin-, metilamidin- és guanidinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
EA200300044A1 (ru) Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции
DE3883140D1 (de) Imidazo(2,1-b)benzothiazole und ihre saeureadditionssalze, verfahren und zwischenprodukte zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zubereitungen.
DK1010698T3 (da) Hidtil ukendte derivater af 1,2-dithiolan, fremgangsmåde til fremstiling deraf og farmaceutiske sammensætninger indeholdende dem
ATE239021T1 (de) Metalloproteaseinhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
WO2002074764A3 (en) Piperazine derivatives and their use as 5-ht1b ligands
DK1188752T3 (da) Fremgangsmåde til fremstilling af substitueret alkylaminderivat
GB1183442A (ko)

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150910